Teva Canada Limited, Medincell's Affiliate, Gains Canadian Approval for Risperidone LAI for Schizophrenia Treatment
I'm PortAI, I can summarize articles.
Teva Canada Limited, an affiliate of Medincell’s partner Teva Pharmaceutical Industries Ltd., has received regulatory approval from Health Canada for risperidone LAI, a treatment for schizophrenia in adults. This approval marks a significant development in the pharmaceutical sector, enhancing treatment options for patients with schizophrenia.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments